Nothing Special   »   [go: up one dir, main page]

WO2014111525A3 - Combination therapies for treating nervous system diseases - Google Patents

Combination therapies for treating nervous system diseases Download PDF

Info

Publication number
WO2014111525A3
WO2014111525A3 PCT/EP2014/050907 EP2014050907W WO2014111525A3 WO 2014111525 A3 WO2014111525 A3 WO 2014111525A3 EP 2014050907 W EP2014050907 W EP 2014050907W WO 2014111525 A3 WO2014111525 A3 WO 2014111525A3
Authority
WO
WIPO (PCT)
Prior art keywords
nervous system
combination therapies
system diseases
treating nervous
alitretinoin
Prior art date
Application number
PCT/EP2014/050907
Other languages
French (fr)
Other versions
WO2014111525A2 (en
Inventor
Mireia COMA
Patrick ALOY
Albert PUJOL
José Manuel MAS
Jordi NAVAL
Caty CASAS
Xavier Navarro
Mireia HERRANDO
Original Assignee
Anaxomics Biotech, Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaxomics Biotech, Sl filed Critical Anaxomics Biotech, Sl
Publication of WO2014111525A2 publication Critical patent/WO2014111525A2/en
Publication of WO2014111525A3 publication Critical patent/WO2014111525A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention is directed to combinations of alitretinoin and pranlukast or to combinations of alitretinoin and mefloquine, to pharmaceutical compositions, kits and treatment methods for the treatment or prevention of nervous system disorders, particularly motor neuron disease, spinal cord disease and/or nervous system disease associated with glutamate excitotoxicity, including amyotrophic lateral sclerosis.
PCT/EP2014/050907 2013-01-18 2014-01-17 New combination therapies for treating nervous system diseases WO2014111525A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361754186P 2013-01-18 2013-01-18
US61/754,186 2013-01-18

Publications (2)

Publication Number Publication Date
WO2014111525A2 WO2014111525A2 (en) 2014-07-24
WO2014111525A3 true WO2014111525A3 (en) 2014-09-12

Family

ID=49998276

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/050907 WO2014111525A2 (en) 2013-01-18 2014-01-17 New combination therapies for treating nervous system diseases

Country Status (1)

Country Link
WO (1) WO2014111525A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102022118B1 (en) * 2019-01-07 2019-09-18 주식회사 아스트로젠 Serine derivative compound for the prevention or treatment of centralnervous system diseases
EP4225306A1 (en) * 2020-10-07 2023-08-16 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101928A0 (en) 1991-07-10 1992-12-30 Max Planck Gesellschaft Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules
US6297254B1 (en) 1999-12-01 2001-10-02 Aventis Pharma S. A. Method for the prevention or treatment of a motoneuron disease
US6933310B1 (en) 2000-10-24 2005-08-23 Mitsubishi Pharma Corporation Therapeutic agent for amyotrophic lateral sclerosis (ALS)
US7541371B2 (en) 2006-02-20 2009-06-02 Eisai R&D Management Co., Ltd. Method for treating a motor neuron disease

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DREW P D ET AL: "Hormone regulation of microglial cell activation: relevance to multiple sclerosis", BRAIN RESEARCH REVIEWS, ELSEVIER, NL, vol. 48, no. 2, 1 April 2005 (2005-04-01), pages 322 - 327, XP027670056, ISSN: 0165-0173, [retrieved on 20050401] *
FANG S H ET AL: "Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats", NEUROSCIENCE; [1068-7971], NEW YORK, NY, US, vol. 140, no. 3, 1 January 2006 (2006-01-01), pages 969 - 979, XP024986799, ISSN: 0306-4522, [retrieved on 20060101], DOI: 10.1016/J.NEUROSCIENCE.2006.02.051 *
ROSSLER J ET AL: "Effect of STI-571 (imatinib mesylate) in combination with retinoic acid and gamma-irradiation on viability of neuroblastoma cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 342, no. 4, 21 April 2006 (2006-04-21), pages 1405 - 1412, XP024923633, ISSN: 0006-291X, [retrieved on 20060421], DOI: 10.1016/J.BBRC.2006.02.059 *
XU J ET AL: "Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 176, no. 1-2, 1 July 2006 (2006-07-01), pages 95 - 105, XP027901385, ISSN: 0165-5728, [retrieved on 20060701] *
XU JIHONG ET AL: "Agonists for the peroxisome proliferator-activated receptor-alpha and the retffionid X receptor inhibit inflammatory responses of microglia", JOURNAL OF NEUROSCIENCE RESEARCH, WILEY-LISS, US, vol. 81, no. 3, 1 August 2005 (2005-08-01), pages 403 - 411, XP002440435, ISSN: 0360-4012, DOI: 10.1002/JNR.20518 *
YU G L ET AL: "Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1053, no. 1-2, 16 August 2005 (2005-08-16), pages 116 - 125, XP027735367, ISSN: 0006-8993, [retrieved on 20050816] *
ZHANG-GANDHI ET AL: "Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 183, no. 1-2, 7 February 2007 (2007-02-07), pages 50 - 59, XP022497009, ISSN: 0165-5728, DOI: 10.1016/J.JNEUROIM.2006.11.007 *

Also Published As

Publication number Publication date
WO2014111525A2 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
EP3526319A4 (en) Compositions and methods for treating diseases and disorders of the central nervous system
EP3429605A4 (en) Therapeutic for treatment of diseases including the central nervous system
WO2013061161A3 (en) New combination therapies for treating neurological disorders
BR112015022597A2 (en) immunity modifying particles for the treatment of inflammation
PT3377637T (en) Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
EP3261721A4 (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease
EP2911664A4 (en) Combination therapies for the treatment of alzheimer's disease and related disorders
MX2015001250A (en) Compositions and treatment for eye diseases and disorders.
EP3507371A4 (en) Methods and compositions for treating diseases and disorders of the nervous system
WO2014151456A3 (en) Treatment of inflammatory diseases
EA201591648A1 (en) BENZIMIDAZOL-2-IL-Pyrimidine modulators of histamine H4 receptor
EP3377118A4 (en) Methods for treating alzheimer's disease and related disorders
EP3618824A4 (en) Use of n-acetylcysteine to treat central nervous system disorders
EA201492102A1 (en) ANTAGONISTS LINGO-2 FOR THE TREATMENT OF DISEASES IN WHICH MOTOR NEURONS PARTICIPATE
EP3606598A4 (en) Method of neural intervention for the treatment of affective neuropsychiatric disorders
EP3566055A4 (en) Methods for the treatment of neurological disorders
EP3154535A4 (en) Composition and method for the treatment of neurological diseases and cerebral injury
EP3324964A4 (en) Amphiphilic pyridinium compounds to treat epilepsy and other disorders of the nervous system
EP3558281A4 (en) Treatment of mental, movement and behavioral disorders
HK1216641A1 (en) 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders 123--4-
MX2017012397A (en) Antibody that recognises the t14 peptide of ache.
EP2814474A4 (en) Methods of treating and preventing diseases and disorders of the central nervous system
EP3052137A4 (en) Methods for the identification, assessment, prevention, and treatment of neurological disorders and diseases using fndc5
WO2015077535A3 (en) Novel methods for treating neurodegenerative diseases
PH12016501159A1 (en) Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14700889

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14700889

Country of ref document: EP

Kind code of ref document: A2